☰

Steven Kalkanis, MD - Publications

Affiliations: 
2014- Neurosurgery Henry Ford Health System 
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zakaria HM, Wilkinson BM, Pennington Z, Saadeh YS, Lau D, Chandra A, Ahmed AK, Macki M, Anand SK, Abouelleil MA, Fateh JA, Rick JW, Morshed RA, Deng H, Chen KY, ... ... Kalkanis S, et al. Sarcopenia as a Prognostic Factor for 90-Day and Overall Mortality in Patients Undergoing Spine Surgery for Metastatic Tumors: A Multicenter Retrospective Cohort Study. Neurosurgery. PMID 32592483 DOI: 10.1093/Neuros/Nyaa245  0.319
2020 Wells M, Asmaro KP, Sabedot TS, Mosella MS, Malta, PharmD TM, Nelson K, Snyder J, deCarvalho A, Mukherjee A, Chitale D, Robin A, Rosenblum ML, Mikkelsen T, Poisson L, ... ... Kalkanis S, et al. OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.542  0.371
2020 Wells M, Asmaro K, Rock J, Sabedot T, Mosella M, Malta T, Nelson K, Snyder J, Kalkanis S, Castro AV, Noushmehr H. Abstract A11: Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A11  0.359
2020 Sabedot T, Malta T, Snyder J, Nelson K, Wells M, deCarvalho A, Mukherjee A, Chitale D, Mosella M, Asmaro K, Robin A, Rosenblum M, Mikkelsen T, Rock J, Poisson L, ... ... Kalkanis S, et al. Abstract A10: Glioma cell-free DNA methylation marker for diagnosis and monitoring Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-A10  0.354
2020 Sabedot TS, Malta TM, She R, Snyder J, Walbert T, Lee I, Kalkanis S, Ewing J, Castro A, Noushmehr H. Abstract 781: Methylation-based liquid biopsy of meningioma primary and recurrent samples Cancer Research. 80: 781-781. DOI: 10.1158/1538-7445.Am2020-781  0.388
2018 de Souza CF, Sabedot TS, Malta TM, Stetson L, Morozova O, Sokolov A, Laird PW, Wiznerowicz M, Iavarone A, Snyder J, deCarvalho A, Sanborn Z, McDonald KL, Friedman WA, Tirapelli D, ... ... Kalkanis S, et al. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Reports. 23: 637-651. PMID 29642018 DOI: 10.1016/J.Celrep.2018.03.107  0.37
2018 Cloughesy TF, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen CC, Kalkanis S, Kesari S, Lai A, Lee I, Liau L, Mikkelsen T, Nghiemphu L, Piccioni D, et al. Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A085  0.363
2018 Sabedot T, deCarvalho A, Poisson L, Snyder J, Walbert T, Lee I, Kalkanis S, Berman B, Noushmehr H. GENE-13. GENOMIC FUNCTIONAL ENHANCERS DEFINE POTENTIAL TUMORIGENESIS OF G-CIMP-LOW (IDH-MUTANT ASTROCYTOMA) TUMORS INDEPENDENT OF PROMOTER METHYLATION Neuro-Oncology. 20: vi105-vi105. DOI: 10.1093/Neuonc/Noy148.439  0.312
2018 Mosella M, Malta T, Sabedot T, Felicella M, Aho T, Poisson L, deCarvalho A, Snyder J, Lee I, Kalkanis S, Walbert T, Noushmehr H, Rock J, Castro AV. GENE-07. GENOMIC ENHANCER METHYLATION IS ASSOCIATED WITH BIOLOGICAL AND CLINICAL FEATURES IN PITUITARY TUMORS Neuro-Oncology. 20: vi104-vi104. DOI: 10.1093/Neuonc/Noy148.434  0.321
2018 Accomando W, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Vogelbaum M, Elder J, Piccioni D, Walbert T, Hogan D, Diago O, Gammon D, Haghighi A, et al. ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7. DOI: 10.1093/Neuonc/Noy148.021  0.304
2017 Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aquirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE Neuro-Oncology. 19: vi30-vi31. DOI: 10.1093/Neuonc/Nox168.116  0.35
2017 Walbert T, Bota D, Vogelbaum M, Kalkanis S, Liau L, Mikkelsen T, Gruber H, Shorr J, Rodriguez-Aguirre M, Ostertag D, Mitchell L, Jolly D, Cloughesy T. SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 19: vi265-vi266. DOI: 10.1093/Neuonc/Nox168.1089  0.371
2017 Cloughesy T, Landolfi J, Vogelbaum M, Ostertag D, Elder B, Carter B, Chen C, Kalkanis S, Lai A, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago O, Hogan D, et al. ATIM-02. DURABLE RESPONSES OBSERVED IN IDH1 WILDTYPE AND MUTANT RECURRENT HIGH GRADE GLIOMA (rHGG) WITH TOCA 511 & TOCA FC TREATMENT Neuro-Oncology. 19: vi26-vi26. DOI: 10.1093/Neuonc/Nox168.099  0.371
2016 Katakowski M, Pikula E, Kalkanis S, Chopp M. Abstract 4641: Bone marrow stromal cells frustrate temozolomide treatment of glioblastoma Cancer Research. 76: 4641-4641. DOI: 10.1158/1538-7445.Am2016-4641  0.304
2016 Ostertag D, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, Chen C, Das A, Jolly D, Gruber H, Vogelbaum M. ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL Neuro-Oncology. 18: vi21-vi21. DOI: 10.1093/Neuonc/Now212.082  0.322
2016 Cloughesy T, Walbert T, Bota D, Vogelbaum M, Liau L, Ostertag D, Jolly D, Gruber H, Yang L, Shorr J, Kalkanis S. ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) Neuro-Oncology. 18: vi17-vi17. DOI: 10.1093/Neuonc/Now212.067  0.304
2015 Ostertag D, Hogan D, Vogelbaum M, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Chen C, Niethammer A, Chu A, Jolly D, Gruber H, Cloughesy T. GENO-30DISTINCT GENE EXPRESSION PROFILE THAT IS NOT A KNOWN SURVIVAL PREDICTOR IN TUMORS FROM LONG-TERM HIGH GRADE GLIOMA SURVIVORS TREATED WITH A RETROVIRAL REPLICATING VECTOR ENCODING YEAST CYTOSINE DEAMINASE Neuro-Oncology. 17: v98.2-v98. DOI: 10.1093/Neuonc/Nov215.30  0.381
2014 Mazaris P, Hong X, Altshuler D, Schultz L, Poisson LM, Jain R, Mikkelsen T, Rosenblum M, Kalkanis S. Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital. Clinical Neurology and Neurosurgery. 120: 103-12. PMID 24731587 DOI: 10.1016/J.Clineuro.2014.03.001  0.36
2014 Cloughesy TF, Kesari S, Kalkanis S, Mikkelsen T, Landolfi J, Elder JB, Liau LM, Chen CC, Bloomfield S, Piccioni D, Chiocca EA, Foltz G, Robbins JM, Ostertag D, Jolly DJ, et al. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION Neuro-Oncology. 16: v110-v111. DOI: 10.1093/Neuonc/Nou258.4  0.394
2014 Kalkanis S, Jolly DJ, Pertschuk D, Ostertag D, Robbins JM, Huang TT, Gruber H, Mikkelsen T. At-29Intravenous Administration Of Toca 511 In Patients With Recurrent Glioblastoma Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.29  0.34
2014 Rosenblum ML, Robin A, Walbert T, Mikkelsen T, Kalkanis S, Rosenblum M. Brain Tumor Care Through The Patient'S Eyes — The Value Of A Comprehensive Brain Tumor Center Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou209.31  0.307
2012 Robbins JR, Ryu S, Kalkanis S, Cogan C, Rock J, Movsas B, Kim JH, Rosenblum M. Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis. Neurosurgery. 71: 937-43. PMID 22806080 DOI: 10.1227/Neu.0B013E31826909F2  0.322
2012 Gates M, Alsaidi M, Kalkanis S. Surgical treatment of solitary brain metastases. Progress in Neurological Surgery. 25: 74-81. PMID 22236669 DOI: 10.1159/000331178  0.342
2010 deCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S, Mikkelsen T. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells (Dayton, Ohio). 28: 181-90. PMID 19937755 DOI: 10.1002/Stem.264  0.305
2009 Rosenblum ML, Kalkanis S, Goldberg W, Rock J, Mikkelsen T, Remer S, Whitehouse S, Nerenz D. Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care. Journal of Neuro-Oncology. 92: 241-51. PMID 19357952 DOI: 10.1007/S11060-009-9828-1  0.336
2007 Barker F, Kalkanis S, McKenna M, Poe D, Nadol J, Ojemann R. Long-Term Radiologic Follow-Up of Tumor Remnants after Subtotal Resection of Acoustic Neuromas Skull Base Surgery. 16. DOI: 10.1055/S-2006-958304  0.318
Show low-probability matches.